Kim Jiwon, Alakbarli Javid, Palumbo Maria Chiara, Xie Lola X, Rong Lisa Q, Tehrani Nathan H, Brouwer Lillian R, Devereux Richard B, Wong Shing Chiu, Bergman Geoffrey W, Khalique Omar K, Levine Robert A, Ratcliffe Mark B, Weinsaft Jonathan W
Greenberg Cardiology Division, Weill Cornell Medicine, New York, New York.
Division of Cardiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Catheter Cardiovasc Interv. 2019 May 1;93(6):1152-1160. doi: 10.1002/ccd.28147. Epub 2019 Feb 21.
To assess impact of left ventricular (LV) chamber remodeling on MitraClip (MClp) response.
MitraClip is the sole percutaneous therapy approved for mitral regurgitation (MR) but response varies. LV dilation affects mitral coaptation; determinants of MClp response are uncertain.
LV and mitral geometry were quantified on pre- and post-procedure two-dimensional (2D) transthoracic echocardiography (TTE) and intra-procedural three-dimensional (3D) transesophageal echocardiography (TEE). Optimal MClp response was defined as ≤mild MR at early (1-6 month) follow-up.
Sixty-seven degenerative MR patients underwent MClp: Whereas MR decreased ≥1 grade in 94%, 39% of patients had optimal response (≤mild MR). Responders had smaller pre-procedural LV end-diastolic volume (94 ± 24 vs. 109 ± 25 mL/m , p = 0.02), paralleling smaller annular diameter (3.1 ± 0.4 vs. 3.5 ± 0.5 cm, p = 0.002), and inter-papillary distance (2.2 ± 0.7 vs. 2.5 ± 0.6 cm, p = 0.04). 3D TEE-derived annular area correlated with 2D TTE (r = 0.59, p < 0.001) and was smaller among optimal responders (12.8 ± 2.1 cm vs. 16.8 ± 4.4 cm , p = 0.001). Both 2D and 3D mitral annular size yielded good diagnostic performance for optimal MClp response (AUC 0.73-0.84, p < 0.01). In multivariate analysis, sub-optimal MClp response was associated with LV end-diastolic diameter (OR 3.10 per-cm [1.26-7.62], p = 0.01) independent of LA size (1.10 per-cm [1.02-1.19], p = 0.01); substitution of mitral annular diameter for LV size yielded an independent association with MClp response (4.06 per-cm [1.03-15.96], p = 0.045).
Among degenerative MR patients undergoing MClp, LV and mitral annular dilation augment risk for residual or recurrent MR, supporting the concept that MClp therapeutic response is linked to sub-valvular remodeling.
评估左心室(LV)腔重构对MitraClip(MClp)治疗反应的影响。
MitraClip是唯一被批准用于治疗二尖瓣反流(MR)的经皮治疗方法,但治疗反应存在差异。左心室扩张会影响二尖瓣的对合;MClp治疗反应的决定因素尚不确定。
在术前和术后二维(2D)经胸超声心动图(TTE)以及术中三维(3D)经食管超声心动图(TEE)上对左心室和二尖瓣的几何形态进行量化。最佳MClp治疗反应定义为早期(1 - 6个月)随访时MR≤轻度。
67例退行性MR患者接受了MClp治疗:虽然94%的患者MR降低≥1级,但39%的患者有最佳治疗反应(MR≤轻度)。治疗反应良好者术前左心室舒张末期容积较小(94±24 vs. 109±25 mL/m²,p = 0.02),相应地瓣环直径也较小(3.1±0.4 vs. 3.5±0.5 cm,p = 0.002),乳头肌间距离也较小(2.2±0.7 vs. 2.5±0.6 cm,p = 0.04)。3D TEE测量的瓣环面积与2D TTE相关(r = 0.59,p < 0.001),且在最佳治疗反应者中较小(12.8±2.1 cm² vs. 16.8±4.4 cm²,p = 0.001)。2D和3D二尖瓣瓣环大小对最佳MClp治疗反应均具有良好的诊断性能(AUC 0.73 - 0.84,p < 0.01)。在多变量分析中,MClp治疗反应欠佳与左心室舒张末期直径相关(每厘米OR 3.10 [1.26 - 7.62],p = 0.01),独立于左心房大小(每厘米1.10 [1.02 - 1.19],p = 0.01);用二尖瓣瓣环直径替代左心室大小与MClp治疗反应存在独立关联(每厘米4.06 [1.03 - 15.96],p = 0.045)。
在接受MClp治疗的退行性MR患者中,左心室和二尖瓣瓣环扩张增加了残余或复发性MR的风险,支持了MClp治疗反应与瓣下重构相关的概念。